Search Prime Grants

R01MH132470

Project Grant

Overview

Grant Description
Strengthening the HIV prevention continuum using pharmacies - Abstract

Early HIV diagnosis is an essential component of the strategy to end the HIV epidemic (EHE). Yet, half of the nearly 40,000 Americans who test positive for HIV every year have late (Stage 3 AIDS) infection, which results in higher community transmission and poorer treatment outcomes.

In the United States South, where HIV is disproportionately impacted, 50% of HIV infections are undiagnosed. Infrequent or delayed HIV testing is most often due to poor healthcare access and stigmatizing attitudes about HIV that inhibit prevention and treatment seeking.

Thus, increased HIV testing access and uptake is urgently needed to normalize HIV testing and direct individuals to pre-exposure prophylaxis (PrEP) if they test HIV negative or HIV treatment if they test HIV positive.

To increase HIV testing access and uptake, we propose integrating HIV prevention services within community pharmacies located in neighborhoods with high HIV prevalence. Despite promising evidence of feasibility of pharmacy-based HIV testing, it is not widely available. In fact, most local pharmacy boards lack policy guidance on HIV testing being within their scope of practice.

Our work has shown that HIV testing uptake in community pharmacies can be increased if it is offered with less stigmatized non-HIV-related services (e.g., COVID19, blood pressure, glucose, and cholesterol screening). But many community pharmacy staff report inadequate training as barriers to integrating HIV testing into the pharmacy work system.

Therefore, to evaluate the implementation and effectiveness of HIV testing and prevention services within community pharmacies, we propose a hybrid Type 1 study design that aims to:

1) Examine the policy-, pharmacy staff-, and client-level barriers and facilitators of adopting HIV prevention services (e.g., HIV testing, PrEP referral, HIV treatment referral) in community pharmacies,
2) Develop and implement pharmacy staff HIV prevention service (e.g., HIV testing and counseling, PrEP referral, HIV treatment referral) trainings, and
3) Test the effects of integrating HIV prevention services in community pharmacies with existing non-HIV-related screenings versus those without on effectiveness and implementation outcomes.

Guided by the Exploration, Preparation, Implementation, Sustainment framework, this study will include an exploration phase that examines the barriers and facilitators to pharmacy-based HIV prevention service provision across the US South using online surveys of community pharmacy staff (N=300), and in-depth interviews of Board of Pharmacy members (N=16) and pharmacy staff (N=40).

In the preparation phase, a virtual community pharmacy HIV prevention training will be developed and offered to 150 community pharmacy staff. Finally, in the implementation and sustainment phase, we will evaluate the acceptability and sustainment of the HIV prevention service delivery over 12 months in 10 community pharmacies (5 pharmacies who offer primary prevention screenings vs. 5 pharmacies who do not).

Findings will be used to support scaling HIV prevention services in community pharmacies in the South where efforts to reduce HIV transmission are desperately needed to EHE.
Funding Goals
NOT APPLICABLE
Place of Performance
Atlanta, Georgia 30322 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 376% from $710,134 to $3,379,222.
Emory University was awarded Pharmacy-Based HIV Prevention Services: Enhancing Access and Uptake Project Grant R01MH132470 worth $3,379,222 from the National Institute of Mental Health in June 2023 with work to be completed primarily in Atlanta Georgia United States. The grant has a duration of 4 years 10 months and was awarded through assistance program 93.242 Mental Health Research Grants. The Project Grant was awarded through grant opportunity Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional).

Status
(Ongoing)

Last Modified 6/5/26

Period of Performance
6/1/23
Start Date
4/30/28
End Date
62.0% Complete

Funding Split
$3.4M
Federal Obligation
$0.0
Non-Federal Obligation
$3.4M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01MH132470

Subgrant Awards

Disclosed subgrants for R01MH132470

Transaction History

Modifications to R01MH132470

Additional Detail

Award ID FAIN
R01MH132470
SAI Number
R01MH132470-3261097878
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75N700 NIH National Institute of Mental Health
Funding Office
75N700 NIH National Institute of Mental Health
Awardee UEI
S352L5PJLMP8
Awardee CAGE
2K291
Performance District
GA-05
Senators
Jon Ossoff
Raphael Warnock

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute of Mental Health, National Institutes of Health, Health and Human Services (075-0892) Health research and training Grants, subsidies, and contributions (41.0) $785,901 100%
Modified: 6/5/26